Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit of TIVICAY in the indication “treatment of Human Immunodeficiency Virus (HIV)-infected adults and adolescents above 12 years of age” is substantial in antiretroviral naïve patients and in experienced patients with prior treatment failure. |
Clinical Added Value
| moderate |
In patients who have no therapeutic options and whose virus is susceptible to dolutegravir :
The Transparency Committee considers that TIVICAY (dolutegravir), in combination with an optimised background regimen, provides a moderate improvement in actual benefit (level III) in terms of immunological and virological efficacy in therapeutic management. |
| minor |
In antiretroviral-naïve or experienced patients whose virus does not have integrase inhibitor (INI) resistance mutations :
The Transparency Committee considers that TIVICAY (dolutegravir) incombination with other antiretrovirals provides a minor improvement in actual benefit (level IV) compared with raltegravir (ISENTRESS) due to having an immunological and virological efficacy that is not inferior to that of raltegravir with a higher genetic barrier to the development of resistance and better ease of use than raltegravir (a single dose versus two daily doses in the case of raltegravir). |
See also
HAS opinions and decisions
05/03/2014
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
JXF7GQmG9SyXp98y
